ArticleJournal of the Pediatric Infectious Diseases Society2025
SARS-CoV-2 Vaccine-Elicited Antibody Responses in Human Milk.
Article in Journal of the Pediatric Infectious Diseases Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundSARS-CoV-2 mRNA-LNP immunizations significantly reduce severe coronavirus disease 2019 (COVID-19) disease and have been widely administered throughout the world including those who are pregnant and postpartum. However, our understanding of the immune response within the context of pregnancy and breastfeeding, especially the antibody kinetics and function within the breast milk compartment, is limited. To address this gap, we studied longitudinal blood and breast milk samples from lactating women throughout the primary immunization schedule and for several months after. The overarching goal of this study is to delineate the antibody kinetics, binding breadth, and neutralization capacity of SARS-CoV-2 mRNA-LNP vaccine-elicited antibodies within the breast milk compartment and compare to that in serum.
methodsWe enrolled 13 participants prior to receiving SARS-CoV-2 immunization. We measured anti-SARS-CoV-2 Spike IgG or IgA in serum and self-collected breast milk in participants over a 6-month period. Breast milk was processed by removing lipids and cellular debris by cold centrifugation, and skim milk was then filtered for binding antibody multiplexed assays and neutralization assays.
resultsPostpartum immunization with a SARS-CoV-2 mRNA-LNP vaccine elicits a robust IgG response and moderate IgA response in serum, which is transferred to breast milk. Serum was able to neutralize pseudovirus after completion of the vaccine schedule. These responses persisted for several months predominantly in persons with a potential history of SARS-CoV-2 infection.
conclusionsImmunization elicits persistent anti-SARS-CoV-2 breast milk antibody responses. We found that hybrid immune individuals had enhanced neutralization and anti-Spike IgG in breast milk and serum. The impact of breast milk antibody on infant anto-SARS-CoV-2 immune responses requires further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.